Pre-irradiation carboplatin and etoposide and accelerated hyperfractionated radiation therapy in patients with high-grade astrocytomas: A phase II study

Radiotherapy and Oncology

Volumn 51, Issue 1, 1999, Pages 27-33

  Jeremic, Branislav ^a   Shibamoto, Yuta ^b   Grujicic, Danica ^c   Milicic, Biljana ^a   Stojanovic, Miroslav ^a   Nikolic, Nebojsa ^a   Dagovic, Aleksandar ^a   Aleksandrovic, Jasna ^a  

^a University Hospital   (Serbia)

^b Clinical Hospital Centre   (Serbia)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Accelerated hyperfractionated radiation therapy; Carboplatin; Etoposide; High grade astrocytomas; Pre irradiation chemotherapy

Indexed keywords

CARBOPLATIN; ETOPOSIDE;

ADULT; AGED; ALOPECIA; ARTICLE; ASTROCYTOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; HUMAN; LEUKOPENIA; MALE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0032981132     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(99)00029-8     Document Type: Article

References (38)

1. Assieti R., Butti G., Magrassi L., Danova M., Riccardi A., Gaetani P. Cell-kinetic characteristics of humnan brain tumors. Oncology. 47:1990;344-351.
2. Buatti J.M., Marcus R.B., Mendenhall W.M., Friedman W.A., Bova F.J. Accelerated hyperfractionated radiotherapy for malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 34:1996;785-792.
3. Chang C.H., Horton J., Schoenfeld D., et al. Comparison of post-operative radiotherapy and combined post-operative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer. 52:1983;997-1007.
4. Cox J.D., Stetz J.A., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for the Research and Treatment of Cancer (EORTC). Int. J. Radiat. Oncol. Biol. Phys. 31:1995;1341-1346.
5. Coyle T., Bushunow P., Marsh S., et al. MOP chemotherapy followed by radiotherapy for high grade glioma (abstr.). Proc. Am. Soc. Clin. Oncol. 14:1995;154.
6. Curran W.J., Scott C.B., Nelson J., et al. A randomized trial of accelerated hyperfractionated radiation therapy and bis-chlorethyl nitrosourea for malignant glioma. Cancer. 70:1992;2909-2917.
7. Deutch M., Green S.B., Strike T.A., et al. Results of randomized trial comparing BCNU plus radiotherapy, streptozocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidasole plus radiotherapy in the post-operative treatment of malignant glioma. Int. J. Radiat. Oncol. Biol. Phys. 16:1989;1389-1396.
8. Dixon D.O., Simon R. Sample size considerations for studies comparing survival curves using historical controls. J. Clin. Epidemiol. 41:1988;1209-1213.
9. Eyre H.J., Quagliana J.M., Eltringham J.R. Randomised comparisons of radiotherapy and CCNU vs. radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery. A Southwest Oncology Group report. J. Neuro-Oncol. 1:1983;171-177.
10. Fetell M.R., Grossman S.A., Belmaceda C., et al. Clinical and pharmacologic study or pre-irradiation paclitaxel in newly diagnosed patients with glioblastoma multiforme (Abstr.). Proc. Am. Soc. Clin. Oncol. 13:1994;179.
11. Friedman H.S., Krischer J.P., Burger P., et al. Treatment of children with progressive of recurrent brain tumors with carboplatin or iproplatin; A pediatric oncology group randomzied phase II study. J. Clin. Oncol. 10:1992;249-256.
12. Gonzalez D.G., Menten J., Bosch D.A., et al. Accelerated radiotherapy in glioblastoma multiforme: a dose searching prospective study. Radiother. Oncol. 32:1994;98-105.
13. Green S.B., Byar D.P., Walker M.D. Comparison of carmustine, procarbazine, and high-dose methylprdnisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat. Rep. 67:1983;121-132.
14. Grossman S.A., Wharam M., Sheidler V., et al. Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J. Clin. Oncol. 15:1997;2596-2603.
15. Horiot J.C., van der Bogaert W., Ang K.K., et al. EORTC trials using radiotherapy with multiple fractions per day, a 1978-1987 survey. Vaeth J. M., Meyer J., et al. Frontiers of Radiation Therapy and Oncology. 22:1988;149 Karger, Basel.
16. Hoshino T., Wilson C.B. Cell kinetic analyses of human malignant brain tumors (gliomas). Cancer. 44:1979;956-962.
17. International Commission on Radiological Units and Measurements. Dose specification for reporting external beam therapy with photons and electrons, ICRU Report No., 29: 3-13, 1978.
18. Jeremic B., Grujicic D., Jevremovic S., et al. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: A phase II study. J. Clin. Oncol. 10:1992;1074-1077.
19. Jeremic B., Grujicic D., Antunovic V., Djuric Lj., Stojanovic M., Shibamoto Y. Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: A phase II study. Int. J. Radiat. Oncol. Biol. Phys. 30:1994;1179-1185.
20. Jeremic B., Grujicic D., Antunovic V., Djuric Lj., Shibamoto Y. Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study. Am. J. Clin. Oncol., (CCT). 18:1995;449-453.
21. Kristiansen K., Hagen S., Kollevold T., et al. Combined modality therapy of operated astrocytomas Grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the Scandinavian Glioblastoma Study group. Cancer. 47:1981;649-652.
22. Levin V.A., Silver P., Hannigan J., Wara W.M., Gutin P.H., Davis R.L., Wilson C.B. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic astrocytoma: NCOG 6G91 final report. Int. J. Radiat. Oncol. Biol. Phys. 18:1990;321-324.
23. Loeffler J.S., Alexander E., Kooy H.M., Wen P.Y. Results of radio-surgery used in the initial management of patients with malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 21:1991;171.
24. Madajevicz S., Meek A., Davis R., et al. Novel first line therapy for malignant astrocytomas (Abstr.). Proc. Am Soc. Clin. Oncol. 13:1994;178.
25. Mehta M.P., Masciopinto J., Rozental J., et al. Stereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Int. J. Radiat. Oncol. Biol. Phys. 30:1994;541-549.
26. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
27. Nelson D.F., Urtasun R., Saunders W., et al. Recent and current investigations of radiation therapy of malignant gliomas. Semin. Oncol. 13:1986;46-55.
28. Nelson D.F., Diener-West M., Horton J., et al. Combined modality approach to treatment of malignant gliomas. Re-evaluation of RTOG 7401/ECOG 1374 with long-term follow up. A joint RTOG-ECOG study. Natl. Cancer Inst. Monogr. 6:1988;279-284.
29. Nelson D.F., Diener-West M., Weinstein A.S., et al. A randomized comparison of misonidasole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study. Int. J. Radiat. Oncol. Biol. Phys. 12:1986;1793-1800.
30. Nelson D.F., Curran W., Scott C., et al. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma: possible advantage observed at 72.0 Gy in 1.2 Gy b.i.d. fractions: report of the Radiation Therapy Oncology Group protocol 8302. Int. J. Radiat. Oncol. Biol. Phys. 25:1993;193-207.
31. Shapiro W.R., Green S.B., Burger P.C., et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in post-operative treatment of malignant glioma. J. Neurosurg. 71:1989;1-9.
32. Shibamoto Y., Shibata T., Miyatake S., et al. Assessment of proliferative activity and radiosensitivity of human tumors using the cytokinesis-block micronucleus assay. Br. J. Cancer. 70:1995;67-71.
33. Shibamoto Y., Nishimura Y., Tsutsui K., Sasai K., Takahashi M., Abe M. Comparison of accelerated hyperfractionated radiotherapy and conventional radiotherapy for supratentorial malignant glioma. Jpn. J. Clin. Oncol. 27:1997;31-36.
34. Sneed P.K., Gutin P.H., Larson D.A., et al. Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int. J.Radiat. Oncol. Biol. Phys. 29:1994;719-727.
35. Stewart D.J., Belanger J.M., Grahovac Z., et al. Phase I study of intracarotid administration of carboplatin. Neurosurgery. 30:1992;512-517.
36. Thames H.D., Peters L.J., Withers H.R., Fletcher G.H. Accelerated fractionation versus hyperfractionation: rationales for several treatments per day. Int. J. Radiat. Oncol. Biol. Phys. 9:1983;127-138.
37. Tirelli U., Dincalci M., Canneta R., et al. Etoposide (VP-16-213) in malignant brain tumors. A phase II study. J. Clin. Oncol. 2:1984;432-437.
38. Williams P.C., Henner D., Roman-Goldstein S., et al. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain-barrier in the treatment of intracranial neo plasms. Neurosurgery. 37:1995;17-28.